Search
Tisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTF is a novel target for cancers, as it is often overexpressed on solid tumours, including cervical cancer, and it is associated with poor clinical outcomes. … TF is a primary initiator of the extrinsic blood coagulation cascade [L38424] and plays a key role in tumor-associated angiogenesis, progression, and metastasis for tumor survival.
Tetrachlorodecaoxide
go.drugbank.com/drugs/DB05389ApprovedThe trial is being conducted in Germany at the University of Heidelberg and the National Centre for Tumor Diseases. … The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the
Categories: Compounds used in a research, industrial, or household settingAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnAsunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. … It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UsePexidartinib
go.drugbank.com/drugs/DB12978ApprovedInvestigational[L7901] While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime … Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexInositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnInositol nicotinate, also known as Inositol hexaniacinate/hexanicotinate or "no-flush niacin", is a niacin ester and vasodilator. … Inositol nicotinate is prescribed in Europe under the name Hexopal as a symptomatic treatment for severe intermittent claudication and Raynaud’s phenomenon.
Ursodeoxycholic acid
go.drugbank.com/drugs/DB01586ApprovedInvestigational[A256272,A256277] UDCA has been used to treat liver disease for decades: its first use in traditional medicine dates back more than a hundred years. … Ursodeoxycholic acid (UDCA), also known as ursodiol, is a naturally-occurring bile acid that constitutes a minor fraction of the human bile acid pool.
Products: URSO 1A PHARMA 250MG, URSO 1A PHARMA 400MGThiethylperazine
go.drugbank.com/drugs/DB00372ApprovedInvestigationalWithdrawnThis piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) … A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins.
Categories: Antihistamines for Systemic UseSerum paraoxonase/arylesterase 1
go.drugbank.com/bio_entities/BE0000930TargetEnzymeHumansHydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic pr...
Synonyms: PON, PON 1Digoxin Immune Fab (Ovine)
go.drugbank.com/drugs/DB00076ApprovedDigoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.
Brodalumab
go.drugbank.com/drugs/DB11776ApprovedInvestigationalBrodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
Categories: Interleukin-17 Receptor A Antagonist, Interleukin 17 Receptor A Antagonists